Alzheimer’s Disease – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report. In addition to forecasting lifetime prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in high-income countries.

Clarivate Epidemiology’s AD forecast will answer the following questions:

• Of all people diagnosed with AD, how many in each high-income country are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following patient populations:

• Total prevalent cases of asymptomatic AD.
• Total prevalent cases of mild cognitive impairment (MCI) due to AD by symptoms (agitation, depression, hallucinations).
• Total prevalent cases of symptomatic MCI due to AD by diagnosis status.
• Total prevalent cases of AD.
• Total prevalent cases of AD by severity (mild, moderate, severe).
• Total prevalent cases of AD by diagnosis status.
• Diagnosed prevalent cases of AD by symptom status (agitation, depression, hallucinations).
• Diagnosed prevalent cases of MCI due to AD by drug-treatment status.
• Diagnosed prevalent cases of AD by drug-treatment status.
• Diagnosed prevalent cases of mild AD by drug-treatment status.
• Diagnosed prevalent cases of moderate AD by drug-treatment status.
• Diagnosed prevalent cases of severe AD by drug-treatment status.

… and many more (details available on request).

Note: Coverage may vary by country and region.